Combined VEGFR and MAPK pathway inhibition in angiosarcoma

Medicine & Life Sciences

• trametinib 93%
• Mitogen-Activated Protein Kinases 79%
• Vascular Endothelial Growth Factor A 68%
• cediranib 68%
• Mitogen-Activated Protein Kinase Kinases 43%
• Protein Array Analysis 12%
• Whole Exome Sequencing 11%
• RNA-Seq 11%
• RNA Sequence Analysis 11%
• Extracellular Signal-Regulated MAP Kinases 10%
• Neoplasms 9%
• Formaldehyde 9%
• Paraffin 9%
• Cell Survival 7%
• Endothelial Cells 7%
• Immunohistochemistry 6%
• Clinical Studies 6%
• Gene Expression 5%
• Cell Line 5%
• Drug Therapy 5%
• Mutation 5%
• Mortality 5%
• Therapeutics 4%
• In Vitro Techniques 4%
• Proteins 3%